Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Signalling and Men > Pharmacokinetics of the gays > Flashcards

Pharmacokinetics of the gays Flashcards

1
Q

(1) Process of administraction

A

1) Absorption
2) Distribution
3) Metabolism
4) Elimination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

(1) Bioavailability

A

Proportion of dose that reaches the site of action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

(1) Intravenous injection

A 
PROS
100% Bioavailbility 
CONS
-Sterile equipment 
-Trained personnel 
-Expensive 
-Potentially painful
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

(1) Oral route

A

PROS
Safest, most convenient and economical route
CONS
-Less than 100% Bioavailablility (due to enzymes and pH
-Complex with good
-Requires patient compliance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

(1) Fick’s law of passive diffusion

A

Rate = Permeability x surface area x conc diff / thickness of membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

(1) Other methods of absorption (not including passive diffusion)

A
  • Active transport
  • Ion-pair absorption
  • Pinocytosis
  • Solvent drag
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

(1) Sites of drug absorption

A

MAIN: Small intestine with large surface area

LITTLE AB: Stomach and colon due to small surface area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

(1) Examples of orally administered drugs with problems

A

Aspirin: Irritate stomach and nausea
Tetracyclines: Chelate metals so absorption reduced by milk and iron preparations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

(1) WAT is first-pass metabolism

A

After absorption, drugs enter portal system (some drugs rapidly metabolised by liver and gut wall)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

(1) Inhalation

A

Lipid soluble anaethetics: rapid absorption

Avoids first pass

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

(1) Transdermal

A

Outer layer (stratum corneum) rate limiting step
-Low input rate
E.g. Nicotine patches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

(1) Buccal/sublingual

A 
Passive absorption (saliva may wash away)
(e.g. GTN for angina)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

(1) Intranasal

A

Epithelial metabolism, passive diffusion

e.g. GTN for angina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

(1) Rectal

A

Only middle and lower rectum avoid FPM

- Passive diffusion
e. g. Diazepam rectal tubes for status epilepticus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

(1) Subcutaneous (under dermis)

A

Only small volumes, passive diffusion, dependent on blood flow
(e.g. vaccines and insluin/GH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

(1) Intramuscular injection

A

LARGE blood flow
-Quick uptake into body

CONS

  • No self administration
  • Can be painful

(e.g. vaccines, antipsychotic drugs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

(1) Only free drug is active and eliminated

A

COURAGE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

(1) Factors in tissue distribution

A

1) Lipid solubility
2) Plasma protein binding
3) Molecular weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

(1) WAT is blood-brain barrier

A
  • Layer of tightly joined endothelial cells
  • Prevents many drugs entering brain
  • Lipid soluble drugs pass by passive diff
  • Water soluble drugs only pass via carrier mechanisms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

(1) WAT happens to drugs in metabolism

A

1) Converted to inactive metabolties
2) Converted to active metabolites
3) Some drugs are excreted unchanged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

(1) Phases of drug metabolism

A

Phase 1: Transforms molecular structure of drug
(Example: Oxidation, hydrolysis, reduction)
Induce polar group/increase water solubility

Phase 2: Conjugation

  • Attaches an endogenous substance (e.g. sulphate) to parent drug or phase 1 metabolite
  • Increases water solubility so it can be elminated in urine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

(1) Main excretion route

A

Renal: Only unbound drug is excreted

Lipid soluble drugs can be reabsorbed in renal tubules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

(2) What defines estimated volume of distribution

A

Warfarin
-Low lipid solubility + low tissue binding

Amitriptyline
-High lipid solubility + tissue binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

(2) VAS IS DAS Clearance

A

Rate of elimination/conc of input

-Represents virual volume of blood cleared of drug per unit time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

(2) Creatinine clearance

A

Renal clearance of drugs varies linearly with creatinine clearance
(Creatinine is break down product of creatine phosphate in muscle)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

(2) First order elimination kinetics

A

Rate of elimination of proportional to drug concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

(2) Half-life

A

This is the time taken for the drug conc to fall by half

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

(2) DISTRIBUTION and ABSORPTION IS A FIRST ORDER PROCESS BRO

A

Retard

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

(2) Zero order kinetics

A

Rate of elimination is not proportional to drug conc but is constant

(e.g. High dose aspirin)
Half-life is not constant but depends on starting concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

(2) Therapeutic drug monitoring

A

Measuring drugs conc in body to determine most effective dose/avoid toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

(2) Drugs via therapeutic drug monitoring

A
  • Cardiac drugs: (digoxin due to narrow theraputic)

- Immunosuppressants: Cyclosporin (prevent rejection)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

(2) Use of urine sampling

A
  • No blood sample needed

- Good for drugs that are eliminted in urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

(3) 4 types of receptors`

A

1) Ligand gated ion channels (ionotropic)
2) GPCR (metabotropic)
3) Kinase-linked R
4) Receptors linked to gene transcription (Nuclear receptors)

34
Q

(3) Responses due to agonists

A
  • Muscle contraction
  • Change in membrane potential
  • Production of 2nd messenger
  • Inhibition of transmitter release
35
Q

(3) Maximum response

A

1) Finite number of receptors: all occupied
2) Property of tissue/cell
(e. g. maximum muscle contraction)

36
Q

(3) Affinity

A

How well a drug binds to the receptor

37
Q

(3) Efficacy

A

Measure of the response of the receptor once drug is bound

38
Q

(3) Potency

A

Combination of both affinity and efficacy

39
Q

(3) How to measure ligand affinity

A

Ligand binding assay using radio-labelled ligand (must account for non-specific binding)

40
Q

(3) Desensitisation/Tachyphylaxis

A

1) Receptor modification (phosphoylation)
2) Loss of receptors (internalisation)
3) Exhaustion of mediators
4) Physiological adaptation (homeostatic response)

41
Q

(3) Clinical use of agonists

A

Adrenaline (Heart: Increase heart rate)
Salbutamol (asthma)
Dopamine (heart, increase rate and force contraction)

42
Q

(3) Partial agonists

A

Cannot product a maximal response

43
Q

(3) Clinical use of partial agonists

A

Buprenorphine (Temgesic)

-Less abuse liability

44
Q

(3) Inverse agonists

A

Reduce activity of GPCRs that are active in absence of ligand (activity too low to be important in physiological states)

(e.g. IA decrease opening of GABA-A receptor)

45
Q

(3) Competitive antagonists

A

Increase EC50

  • Have zero efficacy
  • Shift to the ring
46
Q

(3) Use of competitive receptor antagonists

A
  • B-blockers (heart hypertension)

- Tubocurarine: nicotinic R antagonist (muscle relaxant)

47
Q

(3) Non-competitive R antagonists

A

Cannot reach maximum response

48
Q

(3) Spare receptors

A

Not all 100% of receptors are needed to get full response

  • Don’t need to occupy all R for full response
  • Kd doesnt equal EC50.
49
Q

(3) Use dependency

A

The greater a receptro/ion channel is activated the greater the block
(Mech: Open channel block or binding to inactivated state)

50
Q

(4) Changes by Anaesthesia

A

1) Unconsciousness
2) Loss of response to pain (analgesia)
3) Loss of reflexes

51
Q

(4) Local aneasthetics

A

Act locally to block nerve conduction

52
Q

(4) General anaesthetics

A

Act in the brain to cause loss of consciousness (Used for operations)

53
Q

(4) stages of anaesthesia

A

STAGE 1

  • Still awake but drowsy
  • Distorted perception
STAGE 2
-Loss of conscinousness 
-Stimulation of CNS (uncontrolled movements)
-Irregular breathing 
Dangerous phase: Move through as fast

STAGE 3 (surgical)

  • Regular breathing
  • Cough + vomit reflex depressed
  • Large skeletal muscles relax

STAGE 4

  • Breathing becomes shallow and feeble pulse
  • No ventilation due to depression of medulla oblongata
54
Q

(4) How can depth of anaesthesia be measured?

A

Using EEG

55
Q

(4) Lipid theory

A

GA agents dissolve in mem:
-Changes bilayer thickness, order parameters, curvature elasticity

EVIDENCE

1) Pressure reversal
2) No defined chemcial structure of GAs
3) Meyer-Overton correlation

56
Q

(4) Problems with lipid theory

A

1) Stereoisomers
2) New compounds don’t fit Meyer-Overton correlation
3) Increase carbon chain length (cut off effect)
4) Non-immobilisers
5) Small increases in temperature produce similar changes than GA
6) Similar correlation with partition of GAs into protein

57
Q

(4) Protein theory

A

GA bind specific mem proteins

1) GABAa R (inhibit)
2) 2 pore K+ channels (control resting potential)
3) NMDA R (excitatory)

58
Q

(4) Criteria for identifying relevant anaesthetic protein targets

A

1) Reversibly alters target function at clinically relevant conc
2) Target expressed in appropriate anatomical location in brain/spinal cord
3) Stereo selective effects in-vivo parallel actions on target in vitro
4) Target exhibits appropriate sensitivity/insensitivity to model and non-anaesthetic compounds

59
Q

(4) Properties of ideal anaesthetic

A

1) Rapid action +recovery
2) Minimal irritant properties
3) Miscidble with air/oxygen (doesnt explode)
4) analgesic
5) Muscle relaxant

60
Q

(4) Minimum alveolar concentration (MAC)

A

Alveolar partial pressure of an inhaled anesthetic, which prevents movement in response to a standard noxious stimulus in 50% of patients

61
Q

(4) Pharmacokinetics of inhaled agents

A

1) Greater solubility in blood (determined by blood/gas co-efficent)
2) Reduced rate of rise of alveolar partial pressure
3) Reduced rate of rise of brain partial pressure
4) Slower rate of anaesthesia onset

62
Q

(4) Recovery from anaesthesia

A

Elimination of inhaled anaesethetics mainly by ventilation through lungs

63
Q

(4) Factors decreasing length of recovery

A

1) Reduction of inspired concentration
2) High alveolar ventilation
3) Low blood gas solubility
4) Short duration of anaesthesia

64
Q

(4) Intravenous anaesthetics

A

Propofol

  • GABAa receptor responses
  • Used as induction agent
  • Metabolised in liver

Thiopental

  • GABAa receptors
  • Highly lipid soluble
  • Poor analgesic and muscle relaxant

Etomidate

  • Induction of anaethesia
  • Rapid recovery

Ketamine

  • Abuse potential and dependance
  • Paediatric anaethesia
65
Q

(4) Inhalation anaesthetics

A

Halothane

  • potent and smooth induction
  • moderate muscle relaxation

Isoflurane

  • Less potent
  • Fall in BP
  • Depress relaxation
  • Muscle relaxation
  • Less risk of hepatotoxicity but less than halothane

Nitrous oxide

  • Maintainance of anaesthesia
  • used in obstetrics
66
Q

(5) Pain

A

An unpleasant sensory and emotional experience assocaited with real or potential tissue damage or described in terms of tissue damage

67
Q

(5) Peripheral pain pathways

A

1) Fast pain (sharp, short duration, well locailised)
A (delta) fibres: myelinated with large diameter
2) Slower pain (dull, diffuse, long lasting, poorly localised)
C fibres:
Unmyelinated
Small diameter

68
Q

(5) A pain pathway

A

Spinothalamic tract

69
Q

(5) Analgesics (pain killers)

A
  • Local anaesthetics (block nerve conduction)
  • General anaesthetics
  • Opioids (morphine)
70
Q

(5) CNS effects of Opioids

A

1) Profound analgesia (without loss of consciousness)
2) Respiratory depression
(reduces PCO2 sensitivity of respiratory centre in medulla)
3) Nausea and vomiting
4) Euphoria
5) Dry mouth
6) Drowsiness
7) Depression of cough reflex
Pinpoint pupils are diagnostic feature of opiate overdose

71
Q

(5) Other effects of opioids

A

1) GI tract
- Increases tone and reduced motility of gut
2) Direct release of histamine (mast cells)
- Bronchocontriction

72
Q

(5) Endogenous ligands for opioid receptors

A

Endorphins and enkephalins
HOW FOUND
1) Made brain extracts
2) Tested extracts on contractions in guinea pig ileum with actions blocked by naloxone

73
Q

(5) Distribution of Opioid receptors

A

Found in areas like PAG, rostral ventral medulla, substantia gelantose)

74
Q

(5) Types of Opioid receptors

A

1) MOP (CNS/periphery)
- Analgesia, respiratory depression
2) DOP (Pontine nuclei)
- Analgesia, key in periphery
3) KOP (Hypothalamus, PAG)
- Analgesia, sediation

75
Q

(5) Central actions on nociceptive pathways

A

1) Inhibition of pain transmission through dorsal horn

2) Inhibit transmitter release from primary afferents

76
Q

(5) Effects of injecting morphine into PAG

A
  • Analgesia
  • MOP R in PAG
  • Removes GABA inhibition in PAG to enhance descending inhibition of pain transmission in spinal cord
77
Q

(5) Tolerance

A

Increase in dose required to produce a pharmacological effect

78
Q

(5) Dependence

A

Compulsive craving that develops as a result of repeated administration of drug.

79
Q

(5) Morphine

A

Used for acute and chronic pain

-3-4 hour half life

80
Q

(5) Other examples of opioids

A

Codeine
Pethidine
Methadone

81
Q

(5) Opioid antagonists

A

Naloxone

Used to treat overdose

82
Q

(5) Partial agonists

A

Buprenophine (Temgesic)

Partial agonist at MOP receptors

Signalling and Men (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions